Novo won a European committee recommendation for FREHEMGO and reported strong phase 3 results and easy switching; this increases its sales opportunity in hemophilia A and broadens growth paths.
The CHMP recommendation moves FREHEMGO one step closer to EU approval, which creates a path to sales in adult and pediatric hemophilia A. Strong phase 3 data, easy switching from emicizumab, and a new cardiometabolic research tie increase Novo's product and research optionality.
The story notes Orbis is backed by Eli Lilly, but the deal is between Novo and Orbis and no direct benefit to Lilly is described.
Follow Novo Nordisk A/S (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVO